Latest Regulatory Approval News

Global Lithium Resources Limited has clarified that recent spikes in its share price and trading volume are linked to previously announced project developments, not undisclosed information.

News Corporation has priced a significant secondary offering of over 14 million Class B shares at $32.45 each, marking a notable move by key Murdoch family trusts. The company itself is not raising capital, with proceeds going solely to selling stockholders.

Beacon Minerals has secured critical regulatory approvals for the Iguana Deposit, setting the stage for mining operations and a comprehensive five-year resource development strategy.

Rumble Resources has launched a $9 million capital raise to accelerate development at its Western Queen gold and tungsten projects, targeting near-term production by late 2026. The company also highlights significant resource upgrades and seeks partners for its Earaheedy base metals project.

Rumble Resources has raised $9 million through a combination of institutional placement and entitlement offer to advance its Western Queen gold and tungsten project, targeting production by mid-2026.

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Cosmo Metals has received regulatory approval to commence its first-ever drilling program at the Spring Creek prospect within the Bingara Project, aiming to unlock high-grade gold potential along a historically underexplored 12km trend.

Genesis Minerals has secured regulatory approval for Stage One mining at Tower Hill, aligning the project with its mill expansion plans and setting the stage for production in FY28.

News Corporation has announced a significant secondary offering of over 14 million Class B shares by key family trusts, signaling a notable insider sell-down without direct proceeds to the company.

Kuniko Limited updates its prospectus to extend its entitlement offer, enter a joint venture for the Commonwealth Project, and secure partial underwriting from GBA Capital.

Kuniko Limited has launched a partially underwritten rights issue to fund exploration at its Commonwealth Gold-Silver Project in New South Wales, aiming to capitalise on high-grade multi-metal potential in a Tier-1 jurisdiction.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.